Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Progesterone
All strengths: Off-Formulary Interchangeable, not an ODB benefit; same patient cost rules
Shared coverage and patient cost rules
StatusOff-Formulary Interchangeable, not an ODB benefit
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
ACH-Progesterone · DIN 02549158 · 100 mg · capsule
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
Write on scriptnot an ODB benefit; this DIN is on the ministry's EAP drug list (August 2026): submit an Exceptional Access request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
1 brand, same coverage
ACH-Progesterone · DIN 02549158
Manufacturer: Accord Healthcare Inc.; listing date 2026-04-30
Health Canada: Marketed since 2026-02-11 · brand ACH-PROGESTERONE · ATC G03FA04 PROGESTERONE AND ESTROGEN, G03FA04 PROGESTERONE AND ESTROGEN · form Capsule · route Oral · ingredients PROGESTERONE 100 MG · company Accord healthcare inc · schedule Prescription
ACH-Progesterone: Formulary list price $1.44 per unit (the source does not state the unit; exact figure $1.4358). What the ministry pays, not the patient.
Ministry pays: $1.4358 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02549158).
DIN 02549158: ACH-Progesterone
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 683200098; group id 804; item number 1968; lccId None; manufacturer id ACH
Source form: Cap; strength: 100mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $1.4358; ministry $1.4358
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02549158
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103802Interchangeable products
Auro-Progesterone · DIN 02493578 · $1.4358
M-Progesterone · DIN 02551268 · $1.4358
PMS-Progesterone · DIN 02476576 · $1.4358
Progesterone · DIN 02516187 · $1.4358
Prometrium · DIN 02166704 · not recorded
Reddy-Progesterone · DIN 02463113 · $1.4358
Teva-Progesterone · DIN 02439913 · $1.4358
Shortage status: resolved shortage (ended August 13, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02549158
Shortage record checked October 6, 2026
Auro-Progesterone · DIN 02493578 · 100 mg · capsule
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
Write on scriptnot an ODB benefit; this DIN is on the ministry's EAP drug list (August 2026): submit an Exceptional Access request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
1 brand, same coverage
Auro-Progesterone · DIN 02493578
Manufacturer: Auro Pharma Inc.; listing date 2020-05-29
Health Canada: Marketed since 2020-03-16 · brand AURO-PROGESTERONE · ATC G03DA04 PROGESTERONE · form Capsule · route Oral · ingredients PROGESTERONE 100 MG · company Auro pharma inc · schedule Prescription
Auro-Progesterone: Formulary list price $1.44 per unit (the source does not state the unit; exact figure $1.4358). What the ministry pays, not the patient.
Ministry pays: $1.4358 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02493578).
DIN 02493578: Auro-Progesterone
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 683200098; group id 804; item number 1968; lccId None; manufacturer id AUR
Source form: Cap; strength: 100mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $1.4358; ministry $1.4358
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02493578
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98357Interchangeable products
ACH-Progesterone · DIN 02549158 · $1.4358
M-Progesterone · DIN 02551268 · $1.4358
PMS-Progesterone · DIN 02476576 · $1.4358
Progesterone · DIN 02516187 · $1.4358
Prometrium · DIN 02166704 · not recorded
Reddy-Progesterone · DIN 02463113 · $1.4358
Teva-Progesterone · DIN 02439913 · $1.4358
Shortage status: resolved shortage (ended October 3, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02493578
Shortage record checked October 6, 2026
M-Progesterone · DIN 02551268 · 100 mg · capsule
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
Write on scriptnot an ODB benefit; the ministry's EAP drug list (August 2026) names this generic but not this DIN: confirm the product with the pharmacy or ministry before an Exceptional Access request; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
1 brand, same coverage
M-Progesterone · DIN 02551268
Manufacturer: Mantra Pharma Inc.; listing date 2025-09-29
Health Canada: Marketed since 2025-07-18 · brand M-PROGESTERONE · ATC G03FA04 PROGESTERONE AND ESTROGEN, G03FA04 PROGESTERONE AND ESTROGEN · form Capsule · route Oral · ingredients PROGESTERONE 100 MG · company Mantra pharma inc · schedule Prescription
M-Progesterone: Formulary list price $1.44 per unit (the source does not state the unit; exact figure $1.4358). What the ministry pays, not the patient.
Ministry pays: $1.4358 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02551268).
DIN 02551268: M-Progesterone
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 683200098; group id 804; item number 1968; lccId None; manufacturer id MAT
Source form: Cap; strength: 100mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $1.4358; ministry $1.4358
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02551268
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103999Interchangeable products
ACH-Progesterone · DIN 02549158 · $1.4358
Auro-Progesterone · DIN 02493578 · $1.4358
PMS-Progesterone · DIN 02476576 · $1.4358
Progesterone · DIN 02516187 · $1.4358
Prometrium · DIN 02166704 · not recorded
Reddy-Progesterone · DIN 02463113 · $1.4358
Teva-Progesterone · DIN 02439913 · $1.4358
Shortage status: resolved shortage (ended March 19, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02551268
Shortage record checked October 6, 2026
PMS-Progesterone · DIN 02476576 · 100 mg · capsule
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
Write on scriptnot an ODB benefit; this DIN is on the ministry's EAP drug list (August 2026): submit an Exceptional Access request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
1 brand, same coverage
PMS-Progesterone · DIN 02476576
Manufacturer: Pharmascience Inc.; listing date 2018-11-29
Health Canada: Marketed since 2018-08-08 · brand PMS-PROGESTERONE · ATC G03DA04 PROGESTERONE · form Capsule · route Oral · ingredients PROGESTERONE 100 MG · company Pharmascience inc · schedule Prescription
PMS-Progesterone: Formulary list price $1.44 per unit (the source does not state the unit; exact figure $1.4358). What the ministry pays, not the patient.
Ministry pays: $1.4358 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02476576).
DIN 02476576: PMS-Progesterone
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 683200098; group id 804; item number 1968; lccId None; manufacturer id PMS
Source form: Cap; strength: 100mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $1.4358; ministry $1.4358
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02476576
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96745Interchangeable products
ACH-Progesterone · DIN 02549158 · $1.4358
Auro-Progesterone · DIN 02493578 · $1.4358
M-Progesterone · DIN 02551268 · $1.4358
Progesterone · DIN 02516187 · $1.4358
Prometrium · DIN 02166704 · not recorded
Reddy-Progesterone · DIN 02463113 · $1.4358
Teva-Progesterone · DIN 02439913 · $1.4358
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02476576
Shortage record checked October 6, 2026
Progesterone · DIN 02516187 · 100 mg · capsule
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
Write on scriptnot an ODB benefit; the ministry's EAP drug list (August 2026) names this generic but not this DIN: confirm the product with the pharmacy or ministry before an Exceptional Access request; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
1 brand, same coverage
Progesterone · DIN 02516187
Manufacturer: Sanis Health Inc.; listing date 2021-11-30
Health Canada: Marketed since 2022-08-19 · brand PROGESTERONE · ATC G03DA04 PROGESTERONE · form Capsule · route Oral · ingredients PROGESTERONE 100 MG · company Sanis health inc · schedule Prescription
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02516187).
DIN 02516187: Progesterone
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 683200098; group id 804; item number 1968; lccId None; manufacturer id SAI
Source form: Cap; strength: 100mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $1.4358; ministry $1.4358
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02516187
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100552Interchangeable products
ACH-Progesterone · DIN 02549158 · $1.4358
Auro-Progesterone · DIN 02493578 · $1.4358
M-Progesterone · DIN 02551268 · $1.4358
PMS-Progesterone · DIN 02476576 · $1.4358
Prometrium · DIN 02166704 · not recorded
Reddy-Progesterone · DIN 02463113 · $1.4358
Teva-Progesterone · DIN 02439913 · $1.4358
Shortage status: active shortage (reported May 5, 2026, estimated to end January 8, 2027, last updated October 5, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02516187
Shortage record checked October 6, 2026
Prometrium · DIN 02166704 · 100 mg · capsule
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
Write on scriptnot an ODB benefit; this DIN is on the ministry's EAP drug list (August 2026): submit an Exceptional Access request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
Savings card: RxHelp ONE lists Prometrium (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Prometrium · DIN 02166704
Manufacturer: Organon Canada Inc.; listing date 2015-07-29
Health Canada: Marketed since 2022-02-18 · brand PROMETRIUM · ATC G03DA04 PROGESTERONE · form Capsule · route Oral · ingredients PROGESTERONE 100 MG · company Organon canada inc. · schedule Prescription
Prometrium: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02166704).
DIN 02166704: Prometrium
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 683200098; group id 804; item number 1968; lccId None; manufacturer id OCI
Source form: Cap; strength: 100mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02166704
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18500Interchangeable products
ACH-Progesterone · DIN 02549158 · $1.4358
Auro-Progesterone · DIN 02493578 · $1.4358
M-Progesterone · DIN 02551268 · $1.4358
PMS-Progesterone · DIN 02476576 · $1.4358
Progesterone · DIN 02516187 · $1.4358
Reddy-Progesterone · DIN 02463113 · $1.4358
Teva-Progesterone · DIN 02439913 · $1.4358
Shortage status: resolved shortage (ended February 14, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02166704
Shortage record checked October 6, 2026
Reddy-Progesterone · DIN 02463113 · 100 mg · capsule
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
Write on scriptnot an ODB benefit; this DIN is on the ministry's EAP drug list (August 2026): submit an Exceptional Access request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
1 brand, same coverage
Reddy-Progesterone · DIN 02463113
Manufacturer: Dr. Reddy's Laboratories Inc.; listing date 2018-04-30
Health Canada: Marketed since 2018-08-09 · brand REDDY-PROGESTERONE · ATC G03DA04 PROGESTERONE · form Capsule · route Oral · ingredients PROGESTERONE 100 MG · company Dr. reddy's laboratories inc · schedule Prescription
Reddy-Progesterone: Formulary list price $1.44 per unit (the source does not state the unit; exact figure $1.4358). What the ministry pays, not the patient.
Ministry pays: $1.4358 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02463113).
DIN 02463113: Reddy-Progesterone
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 683200098; group id 804; item number 1968; lccId None; manufacturer id DRR
Source form: Cap; strength: 100mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $1.4358; ministry $1.4358
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02463113
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95102Interchangeable products
ACH-Progesterone · DIN 02549158 · $1.4358
Auro-Progesterone · DIN 02493578 · $1.4358
M-Progesterone · DIN 02551268 · $1.4358
PMS-Progesterone · DIN 02476576 · $1.4358
Progesterone · DIN 02516187 · $1.4358
Prometrium · DIN 02166704 · not recorded
Teva-Progesterone · DIN 02439913 · $1.4358
Shortage status: resolved shortage (ended February 4, 2022); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02463113
Shortage record checked October 6, 2026
Teva-Progesterone · DIN 02439913 · 100 mg · capsule
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
Write on scriptnot an ODB benefit; this DIN is on the ministry's EAP drug list (August 2026): submit an Exceptional Access request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
1 brand, same coverage
Teva-Progesterone · DIN 02439913
Manufacturer: Teva Canada Limited; listing date 2015-07-29
Health Canada: Marketed since 2015-04-16 · brand TEVA-PROGESTERONE · ATC G03DA04 PROGESTERONE · form Capsule · route Oral · ingredients PROGESTERONE 100 MG · company Teva canada limited · schedule Prescription
Teva-Progesterone: Formulary list price $1.44 per unit (the source does not state the unit; exact figure $1.4358). What the ministry pays, not the patient.
Ministry pays: $1.4358 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02439913).
DIN 02439913: Teva-Progesterone
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 683200098; group id 804; item number 1968; lccId None; manufacturer id TEV
Source form: Cap; strength: 100mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $1.4358; ministry $1.4358
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02439913
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92431Interchangeable products
ACH-Progesterone · DIN 02549158 · $1.4358
Auro-Progesterone · DIN 02493578 · $1.4358
M-Progesterone · DIN 02551268 · $1.4358
PMS-Progesterone · DIN 02476576 · $1.4358
Progesterone · DIN 02516187 · $1.4358
Prometrium · DIN 02166704 · not recorded
Reddy-Progesterone · DIN 02463113 · $1.4358
Shortage status: active shortage (reported June 16, 2023, estimated to end February 28, 2027, last updated October 14, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02439913
Shortage record checked October 6, 2026
Other products in the same Health Canada class (G03D): coverage varies; not interchangeable
Dienogest (Visanne): limited Use 432
Medroxyprogesterone acetate
Form:
10 of 10 products shown
7 general benefit · 1 not a benefit · 2 listing conditions apply
AA-Medroxy · DIN 02244726 · 2.5 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
AA-Medroxy · DIN 02244726
Manufacturer: A A Pharma Inc.; listing date 2003-01-30
Health Canada: Marketed since 2024-11-15 · brand AA-MEDROXY · ATC G03DA02 MEDROXYPROGESTERONE · form Tablet · route Oral · ingredients MEDROXYPROGESTERONE ACETATE 2.5 MG · company Aa pharma inc · schedule Prescription
DIN 02244726: AA-Medroxy
Raw flags: sec3=Y
Item: 683200069; group id 801; item number 1959; lccId None; manufacturer id AAP
Source form: Tab; strength: 2.5mg
Recorded listing: General benefit
Source prices (unrounded): $0.1301; ministry $0.1301
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02244726
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68715Interchangeable products
Provera · DIN 00708917 · $0.1301
Shortage status: resolved shortage (ended August 25, 2023); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02244726
Shortage record checked October 6, 2026
AA-Medroxy · DIN 02244727 · 5 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
AA-Medroxy · DIN 02244727
Manufacturer: A A Pharma Inc.; listing date 2003-01-30
Health Canada: Marketed since 2024-12-16 · brand AA-MEDROXY · ATC G03DA02 MEDROXYPROGESTERONE · form Tablet · route Oral · ingredients MEDROXYPROGESTERONE ACETATE 5 MG · company Aa pharma inc · schedule Prescription
DIN 02244727: AA-Medroxy
Raw flags: sec3=Y
Item: 683200011; group id 801; item number 1960; lccId None; manufacturer id AAP
Source form: Tab; strength: 5mg
Recorded listing: General benefit
Source prices (unrounded): $0.2602; ministry $0.2602
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02244727
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68716Interchangeable products
Provera · DIN 00030937 · $0.2602
Shortage status: active shortage (reported September 29, 2026, estimated to end November 20, 2026, last updated October 2, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02244727
Shortage record checked October 6, 2026
AA-Medroxy · DIN 02277298 · 10 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
AA-Medroxy · DIN 02277298
Manufacturer: A A Pharma Inc.; listing date 2007-03-09
Health Canada: Marketed since 2024-11-15 · brand AA-MEDROXY · ATC G03DA02 MEDROXYPROGESTERONE · form Tablet · route Oral · ingredients MEDROXYPROGESTERONE ACETATE 10 MG · company Aa pharma inc · schedule Prescription
DIN 02277298: AA-Medroxy
Raw flags: sec3=Y
Item: 683200061; group id 801; item number 1961; lccId None; manufacturer id AAP
Source form: Tab; strength: 10mg
Recorded listing: General benefit
Source prices (unrounded): $0.5649; ministry $0.5649
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02277298
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76294Interchangeable products
Provera · DIN 00729973 · $0.5649
Shortage status: resolved shortage (ended August 11, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02277298
Shortage record checked October 6, 2026
AA-Medroxy · DIN 02267640 · 100 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
AA-Medroxy · DIN 02267640
Manufacturer: A A Pharma Inc.; listing date 2005-10-06
Health Canada: Marketed since 2024-12-16 · brand AA-MEDROXY · ATC G03DA02 MEDROXYPROGESTERONE · form Tablet · route Oral · ingredients MEDROXYPROGESTERONE ACETATE 100 MG · company Aa pharma inc · schedule Prescription
DIN 02267640: AA-Medroxy
Raw flags: sec3=Y
Item: 683200037; group id 801; item number 1962; lccId None; manufacturer id AAP
Source form: Tab; strength: 100mg
Recorded listing: General benefit
Source prices (unrounded): $1.2057; ministry $1.2057
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02267640
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75305Interchangeable products
Provera · DIN 00030945 · not recorded
Shortage status: resolved shortage (ended November 25, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02267640
Depo-Provera: Formulary list price $34.79 per unit (the source does not state the unit; exact figure $34.7886). What the ministry pays, not the patient.
Ministry pays: $34.7886 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02523493: Depo-Provera
Raw flags: sec3c=Y
Item: 683200118; group id 801; item number 1958; lccId None; manufacturer id PFI
Source form: Inj Sol-1mL Pref Syr; strength: 150mg/mL
Recorded listing: Temporary benefit (shortage substitute)
Source prices (unrounded): $34.7886; ministry $34.7886
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02523493
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101256
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02523493
Temporary benefitOntario PIN; no Health Canada record under this code
StatusTemporary benefit
Write on scriptcheck temporary-benefit rules below
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Depo-Provera · DIN 09858134
Manufacturer: Pfizer Canada Inc.; listing date 2021-05-31
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Depo-Provera: Formulary list price $31.69 per unit (the source does not state the unit; exact figure $31.6900). What the ministry pays, not the patient.
Ministry pays: $31.6900 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 09858134: Depo-Provera
Raw flags: sec3c=Y
Item: 683200117; group id 801; item number 1957; lccId None; manufacturer id PFI
Source form: Inj Sol-1mL Pref Syr; strength: 150mg/mL
Recorded listing: Temporary benefit (shortage substitute)
Source prices (unrounded): $31.6900; ministry $31.6900
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=09858134
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=09858134
Shortage record checked October 6, 2026
Provera · DIN 00708917 · 2.5 mg · tablet
General benefit; Health Canada lists this DIN as Cancelled post market since 2025-11-14 — choose a marketed DIN from the same-category list.Discontinued November 14, 2025 · checked October 5, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2025-11-14 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2025-11-14 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Provera · DIN 00708917
Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01
Health Canada: Cancelled post market since 2025-11-14 · brand PROVERA 2.5MG TABLETS · ATC G03DA02 MEDROXYPROGESTERONE · form Tablet · route Oral · ingredients MEDROXYPROGESTERONE ACETATE 2.5 MG · company Pfizer canada ulc · schedule Prescription
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 00708917).
DIN 00708917: Provera
Raw flags: dinStatus=E, sec3=Y
Item: 683200069; group id 801; item number 1959; lccId None; manufacturer id PFI
Source form: Tab; strength: 2.5mg
Recorded listing: General benefit; DIN status E, meaning unconfirmed
Source prices (unrounded): $0.2567; ministry $0.1301
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00708917
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13037Interchangeable products
AA-Medroxy · DIN 02244726 · $0.1301
Shortage status: discontinued (August 14, 2025, reported by PFIZER CANADA ULC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00708917
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since November 14, 2025 — choose a marketed DIN from the same-category list.
Provera · DIN 00030937 · 5 mg · tablet
General benefit; Health Canada lists this DIN as Cancelled post market since 2025-11-14 — choose a marketed DIN from the same-category list.Discontinued November 14, 2025 · checked October 5, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2025-11-14 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2025-11-14 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Provera · DIN 00030937
Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01
Health Canada: Cancelled post market since 2025-11-14 · brand PROVERA 5MG TABLETS · ATC G03DA02 MEDROXYPROGESTERONE · form Tablet · route Oral · ingredients MEDROXYPROGESTERONE ACETATE 5 MG · company Pfizer canada ulc · schedule Prescription
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 00030937).
DIN 00030937: Provera
Raw flags: dinStatus=E, sec3=Y
Item: 683200011; group id 801; item number 1960; lccId None; manufacturer id PFI
Source form: Tab; strength: 5mg
Recorded listing: General benefit; DIN status E, meaning unconfirmed
Source prices (unrounded): $0.5274; ministry $0.2602
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00030937
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=430Interchangeable products
AA-Medroxy · DIN 02244727 · $0.2602
Shortage status: discontinued (July 3, 2025, reported by PFIZER CANADA ULC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00030937
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since November 14, 2025 — choose a marketed DIN from the same-category list.
Provera · DIN 00729973 · 10 mg · tablet
General benefit; Health Canada lists this DIN as Cancelled post market since 2025-11-14 — choose a marketed DIN from the same-category list.Discontinued November 14, 2025 · checked October 5, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2025-11-14 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2025-11-14 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Provera · DIN 00729973
Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01
Health Canada: Cancelled post market since 2025-11-14 · brand PROVERA 10MG TABLETS · ATC G03DA02 MEDROXYPROGESTERONE · form Tablet · route Oral · ingredients MEDROXYPROGESTERONE ACETATE 10 MG · company Pfizer canada ulc · schedule Prescription
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 00729973).
DIN 00729973: Provera
Raw flags: dinStatus=E, sec3=Y
Item: 683200061; group id 801; item number 1961; lccId None; manufacturer id PFI
Source form: Tab; strength: 10mg
Recorded listing: General benefit; DIN status E, meaning unconfirmed
Source prices (unrounded): $1.0271; ministry $0.5649
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00729973
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=7480Interchangeable products
AA-Medroxy · DIN 02277298 · $0.5649
Shortage status: discontinued (September 22, 2025, reported by PFIZER CANADA ULC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00729973
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since November 14, 2025 — choose a marketed DIN from the same-category list.
Provera · DIN 00030945 · 100 mg · tablet
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2012-02-13 — choose a marketed DIN from the same-category list.Discontinued February 13, 2012 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2012-02-13 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2012-02-13 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Provera · DIN 00030945
Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01
Health Canada: Cancelled post market since 2012-02-13 · brand PROVERA 100MG TABLETS · ATC G03DA02 MEDROXYPROGESTERONE · form Tablet · route Oral · ingredients MEDROXYPROGESTERONE ACETATE 100 MG · company Pfizer canada ulc · schedule Prescription
DIN 00030945: Provera
Raw flags: notABenefit=Y, sec3=Y
Item: 683200037; group id 801; item number 1962; lccId None; manufacturer id PFI
Source form: Tab; strength: 100mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00030945
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=675Interchangeable products
AA-Medroxy · DIN 02267640 · $1.2057
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00030945
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since February 13, 2012 — choose a marketed DIN from the same-category list.
Other products in the same Health Canada class (G03D): coverage varies; not interchangeable
Dienogest (Visanne): limited Use 432
Estradiol hemihydrate & progesterone
All products: general benefit
Bijuva · DIN 02505223 · 1 mg & 100 mg · capsule
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
No interchangeable product listed in the Ontario extract
Bijuva · DIN 02505223
Manufacturer: Knight Therapeutics Inc.; listing date 2024-02-29
Health Canada: Marketed since 2024-01-31 · brand BIJUVA · ATC G03FA04 PROGESTERONE AND ESTROGEN, G03FA04 PROGESTERONE AND ESTROGEN · form Capsule · route Oral · ingredients PROGESTERONE 100 MG, ESTRADIOL (ESTRADIOL HEMIHYDRATE) 1 MG · company Knight therapeutics inc. · schedule Prescription
DIN 02505223: Bijuva
Raw flags: sec3=Y
Item: 681600082; group id 736; item number 1804; lccId None; manufacturer id KNT
Source form: Cap; strength: 1mg & 100mg
Recorded listing: General benefit
Source prices (unrounded): $0.9143; ministry $0.9143
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02505223
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99458
Shortage status: resolved shortage (ended July 10, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02505223
Shortage record checked October 6, 2026
Other products in the same Health Canada class (G03D): coverage varies; not interchangeable
Dienogest (Visanne): limited Use 432
Other drugs in the same formulary classes and how they are covered
Other drugs in the same formulary class (68:16 Estrogens) and how they are covered
Matched class: 68:16 Estrogens
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: ESTRADIOL 17-B, ESTRADIOL HEMIHYDRATE
Some products covered without a code (check the product listing): CONJUGATED ESTROGENS, ESTRADIOL
68:16 Estrogens
Other drugs in the same formulary class (68:32 Progestogens and Oral Contraceptives) and how they are covered
Matched class: 68:32 Progestogens and Oral Contraceptives
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: DESOGESTREL & ETHINYL ESTRADIOL, DROSPIRENONE, DROSPIRENONE & ETHINYL ESTRADIOL, ETHINYL ESTRADIOL & NORETHINDRONE, ETHINYL ESTRADIOL & NORETHINDRONE ACETATE, LEVONORGESTREL
Some products covered without a code (check the product listing): ETHINYL ESTRADIOL & LEVONORGESTREL, NORETHINDRONE, NORGESTIMATE & ETHINYL ESTRADIOL
68:32 Progestogens and Oral Contraceptives
1 INDICATIONS
PROMETRIUM® (progesterone) is indicated for:
women with an intact uterus as an adjunct to postmenopausal estrogen replacement therapy
to significantly reduce the risk of endometrial hyperplasia and carcinoma.
1.1 Pediatrics
Prometrium is not indicated for pediatric use.
1.2 Geriatrics
The evidence of safety and efficacy of Prometrium is limited in women over 65 years of age;
therefore, Prometrium is not indicated in this population.
https://pdf.hres.ca/dpd_pm/00081059.PDF
PM date: May 15, 1995
Source product: PROMETRIUM; DIN 02166704; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1. Indications
AA-MEDROXY (medroxyprogesterone acetate tablets) is indicated for:
• Hormonal replacement therapy, to oppose the effects of estrogen on the endometrium and
significantly reduce the risk of hyperplasia and carcinoma;
• Functional menstrual disorders due to hormonal imbalance in non-pregnant women, in the
absence of organic pathology;
• Adjunctive and/or palliative treatment of recurrent and/or metastatic endometrial
carcinoma;
• Adjunctive and/or palliative treatment of hormonally-dependent, recurrent metastatic
breast cancer in postmenopausal women.
For indications not including breast cancer, AA-MEDROXY should be prescribed only to women
with intact uteri.
1.1. Pediatrics
Pediatrics (<16 years of age): No data are available to Health Canada; therefore, Health Canada
has not authorized an indication for pediatric use.
1.2. Geriatrics
Geriatrics (> 65 years of age): see 7 Warnings and precautions, 7.1.4 Geriatrics.
https://pdf.hres.ca/dpd_pm/00085517.PDF
PM date: 2026-07-24
Source product: AA-MEDROXY; DIN 02244726; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS
BIJUVA (estradiol and progesterone capsule) is indicated for:
• Treatment of moderate to severe vasomotor symptoms associated with menopause in women with
an intact uterus.
BIJUVA is recommended for use only in patients with an intact uterus since the regimen includes a
progestogen whose role is to assist in the prevention of endometrial hyperplasia.
1.1 Pediatrics
Pediatrics (<18 years of age): BIJUVA is not indicated for pediatric use.
1.2 Geriatrics
Geriatrics (>65 years of age): BIJUVA has not been studied in women over 65 years old; therefore,
BIJUVA is not recommended in women over 65 years of age.
https://pdf.hres.ca/dpd_pm/00077597.PDF
PM date: SEP 16, 2020
Source product: BIJUVA; DIN 02505223; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
Availability
Progesterone · DIN 02516187
Shortage status: active shortage (reported 2026-05-05, estimated to end 2027-01-08, last updated 2026-10-05); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02516187
Teva-Progesterone · DIN 02439913
Shortage status: active shortage (reported 2023-06-16, estimated to end 2027-02-28, last updated 2025-10-14); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02439913
AA-Medroxy · DIN 02244727
Shortage status: active shortage (reported 2026-09-29, estimated to end 2026-11-20, last updated 2026-10-02); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02244727
Provera · DIN 00708917
Shortage status: discontinued (2025-08-14, reported by PFIZER CANADA ULC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00708917
Provera · DIN 00030937
Shortage status: discontinued (2025-07-03, reported by PFIZER CANADA ULC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00030937
Provera · DIN 00729973
Shortage status: discontinued (2025-09-22, reported by PFIZER CANADA ULC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00729973
For ACH-Progesterone, Auro-Progesterone, M-Progesterone, PMS-Progesterone, Progesterone, Prometrium, Reddy-Progesterone, Teva-Progesterone, Provera: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.
For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy
Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.
For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)
Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.